Line 78: |
Line 78: |
| * [https://www.cadth.ca/sites/default/files/pcodr/pCODR%27s Drug Review Process/pcodr-clinician_coi-declaration.docx CADTH pan-Canadian Oncology Drug Review disclosure of interest form for clinicians] | | * [https://www.cadth.ca/sites/default/files/pcodr/pCODR%27s Drug Review Process/pcodr-clinician_coi-declaration.docx CADTH pan-Canadian Oncology Drug Review disclosure of interest form for clinicians] |
| * [https://www.cadth.ca/sites/default/files/pcodr/pCODR%27s Drug Review Process/pcodr-patientad-coi-declaratio.doc CADTH pan-Canadian Oncology Drug Review disclosure of interest form for patient groups] | | * [https://www.cadth.ca/sites/default/files/pcodr/pCODR%27s Drug Review Process/pcodr-patientad-coi-declaratio.doc CADTH pan-Canadian Oncology Drug Review disclosure of interest form for patient groups] |
− | * [https://canadiantaskforce.ca/wp-content/uploads/2016/12/procedural-manual-en_2014_Archived.pdf Canadian Task Force on Preventive Healthcare disclosure of interest form] (see Appendix 1) | + | * [https://canadiantaskforce.ca/wp-content/uploads/2020/10/COI-Policy-202008Final-1.pdf Canadian Task Force on Preventive Healthcare disclosure of interest form] (see Appendix 1) |
| * [https://community.cochrane.org/sites/default/files/uploads/EPPR/Cochrane-COI-disclosure-form.pdf Cochrane Collaboration disclosure of interest form] | | * [https://community.cochrane.org/sites/default/files/uploads/EPPR/Cochrane-COI-disclosure-form.pdf Cochrane Collaboration disclosure of interest form] |
| * [https://www.uspto.gov/sites/default/files/documents/OGE450_June_2015.pdf US FDA financial disclosure report – Executive Branch] | | * [https://www.uspto.gov/sites/default/files/documents/OGE450_June_2015.pdf US FDA financial disclosure report – Executive Branch] |
Line 105: |
Line 105: |
| | | |
| === Examples of algorithms/process maps for COI management === | | === Examples of algorithms/process maps for COI management === |
| + | * [https://canadiantaskforce.ca/wp-content/uploads/2020/10/COI-Policy-202008Final-1.pdf Canadian Task Force on Preventive Healthcare algorithm for disclosure of interests and management of COI] (see Appendix 3) |
| * [https://www.atsjournals.org/doi/full/10.1164/rccm.200901-0126ST#_i14 American Thoracic Society COI resolution procedure] | | * [https://www.atsjournals.org/doi/full/10.1164/rccm.200901-0126ST#_i14 American Thoracic Society COI resolution procedure] |
| * [https://cadth.ca/sites/default/files/pcodr/pCODR%27s Drug Review Process/pcodr-coi-guidelines.pdf CADTH pan-Canadian Oncology Drug Review COI management overview] (Appendix A) | | * [https://cadth.ca/sites/default/files/pcodr/pCODR%27s Drug Review Process/pcodr-coi-guidelines.pdf CADTH pan-Canadian Oncology Drug Review COI management overview] (Appendix A) |